InstalabLoading...
InstalabLoading...
When cells in your liver or skeletal muscles are injured, they release their contents into the bloodstream. One of the proteins they release is LDH-5 (lactate dehydrogenase isoenzyme 5), and because this particular form of the enzyme is heavily concentrated in liver and muscle, a rise in your blood LDH-5 acts like an address label on the damage. It tells you not just that something is wrong, but where.
A standard total LDH (lactate dehydrogenase) test adds up the activity of all five isoenzymes (different forms of the same enzyme) together. That total can rise for many reasons, from a heart attack to a blood disorder to strenuous exercise. By measuring LDH-5 separately, you get a more precise answer: the elevation is coming from the liver, from skeletal muscle, or from both. This distinction is what makes isoenzyme testing valuable when the source of an elevated total LDH is unclear.
Lactate dehydrogenase exists in five forms, numbered LDH-1 through LDH-5. Each is built from a different combination of two protein building blocks called the H subunit (heart type) and the M subunit (muscle type). LDH-1 is made entirely of H subunits and is most abundant in heart tissue and red blood cells. LDH-5 sits at the opposite end: it is made entirely of M subunits and is most concentrated in the liver and skeletal muscle.
This tissue-specific distribution is what gives each isoenzyme its clinical meaning. When total LDH is elevated and the lab separates it into its five components, the pattern points toward the organ of origin. A spike in LDH-1 suggests heart or red blood cell damage. A spike in LDH-5 points to the liver or skeletal muscle.
The longest-standing clinical use of blood LDH-5 is as a marker of liver cell injury. Research dating back decades has established that the blood level of LDH-5 rises in direct proportion to the amount of liver cell death occurring. In acute liver conditions like viral hepatitis, LDH-5 rises sharply because large numbers of liver cells are being destroyed in a short period.
A study of 318 people with various liver disorders found that the proportion of LDH-5 relative to total LDH was more sensitive for detecting acute liver injury (such as non-fulminant viral hepatitis) than for identifying chronic liver conditions like cirrhosis. This makes LDH-5 most useful when you suspect an active, ongoing process rather than long-standing scarring.
In alcoholic liver disease, the LDH isoenzyme profile shifts in a recognizable way. The balance between different isoenzymes changes depending on whether the damage is at the stage of alcohol-related inflammation (hepatitis) or has progressed to cirrhosis. This difference reflects the fact that the liver's chemistry changes as healthy tissue is replaced by scar tissue.
Early automated methods for measuring LDH-5 specifically showed it could identify hepatitis and liver tumor involvement before other markers flagged a problem. It was also noted to rise in congestive heart failure (because a failing heart backs up blood into the liver, causing congestion and damage) and in muscle trauma.
LDH-5 appears in cancer research in two very different contexts, and the distinction matters for interpreting your test results. Most published cancer studies measured LDH-5 expression inside tumor tissue using microscopy-based staining (a technique called immunohistochemistry), not in a blood sample. High tissue LDH-5 expression has been linked to poor survival in colorectal cancer, gastric cancer, non-small cell lung cancer, melanoma, non-Hodgkin lymphoma, and prostate cancer. But tissue expression and blood levels are different measurements.
What these tissue studies tell us is that tumors with high LDH-5 are more aggressive. They tend to thrive in low-oxygen environments and build more blood vessels to feed themselves. In colorectal cancer, for example, a study of 128 patients found that high tissue LDH-5 expression was strongly associated with shorter survival. Similar findings appeared in gastric cancer (152 patients), melanoma (159 patients), and non-Hodgkin lymphoma (529 patients).
For blood LDH isoenzyme patterns specifically, a study of 127 people with various cancers found that malignancy was associated with distinct shifts in the isoenzyme profile. The pattern could change after treatment with chemotherapy, radiation, or surgical tumor removal, making serial isoenzyme testing a potential way to monitor treatment response. Blood LDH isoenzyme analysis has also been used to help diagnose liver involvement by metastatic cancer, where it was found to be more accurate than a standard liver enzyme called SGOT (now known as AST, or aspartate aminotransferase).
Because LDH-5 is also abundant in skeletal muscle, blood levels rise when muscles are damaged. In people with hereditary muscle diseases like muscular dystrophy, the LDH isoenzyme pattern shows characteristic changes. Interestingly, muscle tissue from people with muscular dystrophy actually shows reduced LDH-5 activity, reflecting the loss of functional muscle fibers. The enzyme that leaks into the blood comes from dying muscle cells, so the pattern can help distinguish muscular dystrophy from other causes of muscle weakness.
Blood LDH-5 has also been found elevated in asthma patients, where the increase likely reflects liver congestion rather than lung damage. In the cerebrospinal fluid (the liquid surrounding the brain and spinal cord), LDH-5 patterns can help detect and differentiate brain tumors and infections involving the brain's lining.
Many large studies linking LDH to outcomes, such as cancer survival, heart failure prognosis, and severity of infections like COVID-19, measured total blood LDH rather than the LDH-5 fraction specifically. A meta-analysis found that elevated total LDH at hospital admission was associated with roughly a 6-fold increase in the odds of severe COVID-19 and about a 16-fold increase in the odds of death. In heart failure, a study of over 8,000 patients found that higher total LDH levels independently predicted worse outcomes.
These findings are clinically relevant, but they cannot be assumed to apply identically to LDH-5 alone. Total LDH reflects contributions from all five isoenzymes. When you order an LDH-5 test, you are getting a more specific signal. If your total LDH is high and your LDH-5 fraction is the main contributor, that points toward liver or muscle origin. If LDH-1 or LDH-2 dominates instead, the cause is more likely heart, kidney, or red blood cell related.
Standardized reference ranges for blood LDH-5 specifically are not as universally established as those for total LDH. LDH-5 results are typically reported either as an absolute activity in units per liter or as a percentage of total LDH. The exact numbers depend on the laboratory method used, and different separation techniques (such as electrophoresis, which sorts proteins using an electric field) can produce different results for the same sample.
A large multicenter study of 3,511 adults across multiple Asian countries examined LDH isozyme reference intervals and found that LDH-5 values were influenced by age, sex, body mass index (BMI), and blood type. This means a single universal cutpoint does not apply to everyone. Your lab will provide its own reference range, and that is the most reliable number to compare your result against.
In disease-specific contexts, a study of 70 children with Mycoplasma pneumonia found that a combined LDH-4 plus LDH-5 value above 109.4 IU/L helped predict which children would have a more severe, treatment-resistant course. This is a specialized cutpoint for a specific pediatric condition, not a general health threshold.
Because lab methods and reference ranges vary, comparing your results within the same laboratory over time gives you the most meaningful information. A single reading in isolation is less useful than a trend.
LDH-5 can rise temporarily from causes that do not represent a chronic health problem. Intense physical exercise, particularly heavy resistance training or endurance events, can release muscle-derived LDH-5 into the blood for one to three days afterward. If your blood is drawn within this window, your LDH-5 may appear elevated even though your liver and muscles are healthy.
Hemolysis, where red blood cells break open during or after the blood draw, can artificially raise total LDH and distort the isoenzyme pattern. A tourniquet left on too long or a difficult draw can cause this. If your result seems unexpectedly high, ask whether the sample showed signs of hemolysis.
Acute illness, surgery, or significant physical trauma can spike LDH-5 for days to weeks. These elevations are real (they reflect genuine tissue damage) but may not indicate an ongoing chronic condition. Retesting after recovery gives a clearer picture.
Some electrophoretic methods (which separate proteins using an electric field) used to identify LDH isoenzymes can produce inconsistent results due to interactions between the isoenzymes during the separation process. This means that small differences between two readings may reflect laboratory technique rather than a true change in your health.
A single LDH-5 measurement is a snapshot. Because the number can shift with recent exercise, acute illness, or even sample handling, one reading in the normal range does not guarantee your liver and muscles are fine, and one modestly elevated reading does not confirm a problem. The real value comes from tracking your LDH-5 over time.
If you are monitoring a known liver condition or tracking recovery from an acute injury, retesting every few weeks to months lets you see whether the trend is moving in the right direction. In cancer monitoring, sequential LDH isoenzyme measurements have been used to track treatment response, with a falling LDH-5 suggesting that the tumor burden is shrinking.
For baseline health tracking, get an initial measurement when you are feeling well and have not exercised heavily in the prior 48 hours. If it falls within your lab's reference range, recheck it in 6 to 12 months or whenever a clinical question arises. If it is elevated, retest in 2 to 4 weeks after addressing any obvious confounders (recent exercise, illness, or medication changes) before pursuing further investigation.
If your LDH-5 is elevated, the first step is to figure out whether it is coming from the liver, from skeletal muscle, or from both. Companion tests make this straightforward. Liver-specific enzymes like ALT (alanine aminotransferase), AST (aspartate aminotransferase), and GGT (gamma-glutamyl transferase) will be elevated if the liver is the source. Creatine kinase (CK) will be elevated if skeletal muscle damage is responsible, particularly the CK-MM form, which is the fraction found in skeletal muscle.
If liver injury is confirmed, the next questions are what type and how severe. A hepatologist or gastroenterologist can help sort through viral hepatitis panels, imaging, autoimmune markers, and alcohol-related assessments depending on your history. If muscle damage is the source, a neurologist or rheumatologist may be appropriate, particularly if the elevation is persistent and unexplained by recent exercise or trauma.
An isolated, mildly elevated LDH-5 with normal liver enzymes and normal CK is worth rechecking in a few weeks. If it normalizes, no further workup is needed. If it persists, consider broader testing including a complete metabolic panel, total LDH with full isoenzyme fractionation, and imaging of the liver.
Evidence-backed interventions that affect your LDH-5 level
LDH-5 is best interpreted alongside these tests.